Kidney Diseases
|
0.600 |
AlteredExpression
|
group |
BEFREE |
Our results suggest that in aged animals, as compared with Hap-II, the TG mice with Hap-I overexpress hAT1R gene due to the stronger transcriptional activity, thus resulting in an increase in their BP and associated renal disorders.
|
30084918 |
2018 |
Kidney Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
Blockade of the renin-angiotensin system (RAS) with angiotensin-converting enzyme inhibitors and/or angiotensin II type 1 receptor blockers is the most effective treatment to achieve these purposes in non-diabetic and diabetic proteinuric renal diseases.
|
28482281 |
2017 |
Kidney Diseases
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Renin-angiotensin-aldosterone system inhibitors (RAASIs), including angiotensin-converting enzyme inhibitors, angiotensin AT1 receptor blockers and mineralocorticoid receptor antagonists (MRAs), are the cornerstone for the treatment of cardiovascular and renal diseases.
|
28541811 |
2017 |
Kidney Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
The main roles of Ang II in renal disease are mediated via the Ang type 1 receptor (AT1R).
|
25148511 |
2014 |
Kidney Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
In all the three cohorts, a significantly higher frequency of T allele and TT genotypes of ACACβ and C allele and CC genotypes of AGTR1 were found in patients with DN as compared to patients without nephropathy.
|
23081748 |
2013 |
Kidney Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
Therefore, these findings suggest that exogenous activation of the Mas receptor protects from ADR-induced nephropathy and contributes to the beneficial effects of AT1 receptor blockade.
|
23762470 |
2013 |
Kidney Diseases
|
0.600 |
GeneticVariation
|
group |
BEFREE |
No single nucleotide polymorphisms in the ACE2 or AGTR1 genes were significantly associated with nephropathy when analysed either by genotype or allele frequencies.
|
20854388 |
2010 |
Kidney Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
In animal models, interstitial angiotensin II (ang II) and AT1 receptor (AT1R) are key mediators of renal inflammation and fibrosis in progressive chronic nephropathies.
|
20478903 |
2010 |
Kidney Diseases
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The frequency of T allele, MT/TT genotypes (AGT: M235T), and C allele 1166CC genotype (AGTR1: A1166C) was higher and associated with increased risk of DNP (235T, p < 0.0001; 235TT/MT, p < 0.01; 1166C, p < 0.007; 1166CC, p < 0.0001).
|
19108684 |
2009 |
Kidney Diseases
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Three SNPs within the AGT, including M235T and one SNP in the AGTR1, were also significantly associated with nephropathy (M235T P=0.01, odds ratio =0.74, 95% CI 0.59-0.94).
|
17143591 |
2007 |
Kidney Diseases
|
0.600 |
GeneticVariation
|
group |
BEFREE |
There was an association of the AT1R gene polymorphism with the progression of renal disease to end-stage failure.
|
16384824 |
2006 |
Kidney Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
Angiotensin II type 1 receptor (AT1) and angiotensin II type 2 receptor (AT2) genes have been investigated in recent years as potential etiologic candidates for cardiovascular and renal diseases.
|
15756705 |
2005 |
Kidney Diseases
|
0.600 |
Biomarker
|
group |
CTD_human |
However, rats with chronic progressive nephropathy showed augmented renal content of angiotensinogen protein (13.5 +/- 3.5 versus 2.2 +/- 0.4 pixels in control rats; P < 0.05), enhanced expression of cathepsin D-a renin-like enzyme-in cortical collecting tubules (103.5 +/- 27.0 versus 66.2 +/- 3.6 cells/mm2 in controls; P < 0.01), and increased expression of AT1 receptor in interstitium (54.7 +/- 7.8 versus 1.3 +/- 0.4 cells/mm2 in controls; P < 0.001).
|
15213268 |
2004 |
Kidney Diseases
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Recently, the angiotensinogen (AGT) gene, M235T, and angiotensin II type 1 receptor (ATR) gene, A1166C, polymorphisms have been associated with the susceptibility to develop hypertension and renal disease.
|
12950120 |
2003 |
Kidney Diseases
|
0.600 |
GeneticVariation
|
group |
BEFREE |
In order to replicate these findings we performed PCR-based genotyping for the A1166-->C DNA polymorphism and the CA repeat at the 3' end of the angiotensin II (type 1) receptor gene employing validated groups of type 1 diabetic patients with (cases, n = 95) and without (controls, n = 97) nephropathy.
|
10328465 |
1999 |
Kidney Diseases
|
0.600 |
Biomarker
|
group |
BEFREE |
Although the expression of renin and angiotensin-converting enzyme in experimental and human renal disease has been well characterized, no information is available regarding human angiotensin type 1 (AT1) receptor expression.
|
10073605 |
1999 |
Kidney Diseases
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The AT1R and angiotensinogen gene polymorphisms are not associated with progression of renal disease in FSGS.
|
9853248 |
1998 |
Kidney Diseases
|
0.600 |
Biomarker
|
group |
CTD_mouse |
[The expression of AT1A receptor and its modulation by benazepril in the renal tubulointerstitial lesions induced by ureteral obstruction].
|
9596920 |
1997 |
Kidney Diseases
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The aim of this study was to determine the role of the hypertension associated angiotensin II type 1 receptor (AT1R) gene A1166C polymorphism in susceptibility to nephropathy in IDDM.
|
9371475 |
1997 |
Kidney Diseases
|
0.600 |
GeneticVariation
|
group |
BEFREE |
Synergistic effect of angiotensin II type 1 receptor genotype and poor glycaemic control on risk of nephropathy in IDDM.
|
9389421 |
1997 |